PHOENIX ― Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.
Trending
- GI 2.0: The Playbook | Chapter 8 | The AI-Native GI Practice
- The physician referral black hole is swallowing your growth (BPD)
- Could corporate medicine be on the way out? Inside the new federal bill (MDLinx)
- Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (The New England Journal of Medicine)
- Microbiome Holds Biomarker Predictive of CRC Recurrence (GI & Endoscopy News)
- Are You Performing Second Inspection of the Right Colon? (GI & Endoscopy News)
- The AI Is in the Scope. The Evidence Isn’t. (CDO Trends Weekly)
- Updated Diagnostic Criteria for Acute Severe Ulcerative Colitis (Medscape)
